妊娠期接受化疗的乳腺癌患者与非妊娠对照的结局比较
本研究基于两个多中心登记数据库,比较2000年后诊断、接受化疗的妊娠期乳腺癌患者与非妊娠乳腺癌患者的生存结局。共纳入662例妊娠患者和2081例非妊娠对照,中位随访66个月。多因素分析显示两组无病生存(DFS:HR 1.02,95%CI 0.82-1.27,p=0.83)和总生存(OS:HR 1.08,95%CI 0.81-1.45,p=0.59)相当。
要点
- 妊娠期乳腺癌患者接受化疗后DFS和OS与非妊娠年轻患者相当。
- 妊娠患者更多为II期、3级、激素受体阴性或三阴性肿瘤。
- 结果支持有指征时对妊娠期乳腺癌进行化疗。
核心结论
- 妊娠期接受化疗的乳腺癌患者结局与年轻非妊娠乳腺癌患者相当,结果支持有指征时对妊娠期乳腺癌进行化疗。
研究设计与样本
- 数据来自两个多中心登记数据库(国际癌症、不孕与妊娠网络和德国乳腺癌组),纳入2000年后诊断、接受化疗的妊娠期乳腺癌患者与非妊娠乳腺癌患者,排除年龄大于45岁或产后诊断者。
- 共纳入662例妊娠患者和2081例非妊娠对照,采用Cox比例风险回归比较无病生存和总生存,调整年龄、分期、分级、激素受体状态、人表皮生长因子受体2状态和组织学,并以倾向性评分加权处理基线特征差异。
主要发现
- 妊娠患者较非妊娠对照更常见II期乳腺癌(60.1% vs 56.1%,p=0.035)、3级肿瘤(74.0% vs 62.2%,p<0.001)、激素受体阴性肿瘤(48.4% vs 34.0%,p<0.001)和三阴性乳腺癌(38.9% vs 26.9%,p<0.001)。
- 中位随访66个月,多因素分析显示妊娠与非妊娠患者的无病生存(HR 1.02,95%CI 0.82-1.27,p=0.83)和总生存(HR 1.08,95%CI 0.81-1.45,p=0.59)相当。
临床怎么用
- 作者结论认为妊娠期乳腺癌患者接受化疗的结局与非妊娠年轻患者相当,结果支持有指征时对妊娠期乳腺癌进行化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A diagnosis of breast cancer during pregnancy (PrBC) does not impact prognosis if standard treatment is offered. However, caution is warranted as gestational changes in pharmacokinetics may lead to reduced chemotherapy concentration. METHODS: Survival of PrBC patients treated with chemotherapy during pregnancy was compared to non-pregnant breast cancer patients treated with chemotherapy, diagnosed after 2000, excluding patients older than 45 years or with a postpartum diagnosis. The data was registered in two multicenter registries (the International Network of Cancer, Infertility and Pregnancy and the German Breast Group). Cox proportional hazards regression was used to compare disease-free (DFS) and overall survival (OS) between both groups, adjusting for age, stage, grade, hormone receptor status, human epidermal growth factor 2 status and histology, weighted by propensity scoring to account for the differences in baseline characteristics between pregnant patients and controls. RESULTS: In total, 662 pregnant and 2081 non-pregnant patients were selected. Pregnant patients were more likely to have stage II breast cancer (60.1% vs 56.1%, p = 0.035), grade 3 tumors (74.0% vs 62.2%, p < 0.001), hormone receptor-negative tumors (48.4% vs 34.0%, p < 0.001) or triple-negative breast cancer (38.9% vs 26.9%, p < 0.001). Median follow-up was 66 months. In multivariable analysis, DFS and OS were comparable for pregnant and non-pregnant patients (DFS: HR 1.02, 95% CI 0.82-1.27, p = 0.83; OS: HR 1.08, 95% CI 0.81-1.45, p = 0.59). CONCLUSION: Outcome of women with breast cancer treated with chemotherapy during pregnancy is comparable to young non-pregnant women. These results support chemotherapy for PrBC when indicated.
引用
- Amant F, Nekljudova V, Maggen C, et al. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. Eur J Cancer. 2022. PMID: 35594612. doi:10.1016/j.ejca.2022.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。